Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of Brivaracetam in Childhood or Juvenile Absence Epilepsy
NCT06315322Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jul 2024
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of brivaracetam in childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), sponsored by UCB. Started Jul 2024; status: active, not recruiting.
02
Drugs
brivaracetam
03
Conditions
childhood absence epilepsy (CAE)juvenile absence epilepsy (JAE)
Beyond the preview
Go deeper on NCT06315322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315322.